Azenta reported first quarter fiscal 2026 revenue of $149 million and a GAAP operating loss of $7.2 million. The company delivered positive adjusted EBITDA and free cash flow despite gross margin pressure and ongoing turnaround actions.

Azenta reported $159M in revenue and net income of $47.1M in Q4 2025. Growth was driven by strength in Multiomics, while margin expansion supported profitability. GAAP EPS was $1.11 and non-GAAP EPS came in at $0.21.

Azenta delivered a strong performance in an evolving and uncertain macroeconomic environment, with revenue up 5% year over year and adjusted EBITDA up 75% year over year, demonstrating the resilience of its portfolio.

Azenta reported a 4% year-over-year increase in revenue to $148 million, driven by growth in both Sample Management Solutions and Multiomics. The company's adjusted EBITDA margin improved by 400 basis points year-over-year to 9.0%, and non-GAAP diluted EPS remained flat at $0.08.

Azenta's Q4 2024 revenue was $170 million, a 1% decrease year-over-year. However, the combined Sample Management Solutions and Multiomics businesses grew 5% organically. The company reported a diluted EPS from continuing operations of ($0.10) and a non-GAAP diluted EPS of $0.18. They are pursuing the sale of B Medical Systems.

Azenta reported a solid third quarter with revenue of $173 million, a 4% increase year-over-year, and significant margin expansion. The company's organic revenue grew by 5% year-over-year, driven by Sample Management Solutions and B Medical Systems. Adjusted EBITDA was $18 million, with an Adjusted EBITDA margin of 10.3%, reflecting a 260 basis point improvement year-over-year. Non-GAAP diluted EPS was $0.16, compared to $0.13 in the prior year.

Azenta reported a 7% increase in revenue year-over-year, driven by higher B Medical Systems and Sample Management Solutions revenues. The company saw improved profitability due to ongoing cost reduction and transformation initiatives.

Azenta's first quarter results exceeded expectations, with revenue at $154 million. The company has made progress on cost reduction initiatives, leading to the third consecutive quarter of positive free cash flow. While the market environment remains soft, Azenta is positive about its position and expects to continue outgrowing the market throughout fiscal 2024.

Azenta reported a strong fourth quarter with a 25% year-over-year revenue increase and 2% organic revenue growth. The company generated positive free cash flow for the second consecutive quarter and is committing to an additional $500 million in share repurchases in fiscal year 2024.

Azenta reported a strong Q3 2023 with revenue of $166 million, a 25% increase year-over-year. The company saw positive momentum in both organic revenue growth and profitability, driven by go-to-market initiatives and cost reduction efforts. Positive free cash flow was generated during the quarter.

Azenta's Q2 2023 revenue was $148 million, a 2% increase year-over-year. The company reported a diluted EPS from continuing operations of ($0.03) and a non-GAAP diluted EPS from continuing operations of ($0.06). A business realignment was announced to enhance commercial strategy and profitability.

Azenta reported a strong first quarter for fiscal year 2023, with revenue reaching $178 million, a 28% increase year-over-year. Organic growth, excluding COVID impacts, was 7%. The company has also begun efforts to streamline its business structure to enhance operational efficiency.

Azenta reported Q4 2022 revenue of $138 million, flat year over year. Non-GAAP diluted EPS was $0.16, up from $0.12 in the prior year. The company's Board authorized a $1.5 billion share repurchase program.

Azenta's Q3 2022 results were below expectations due to lower revenue from consumables and genomics, despite delivering 6% organic growth year-over-year driven by storage services and automated ultra-cold storage systems.

Azenta Life Sciences reported preliminary financial results for Q2 2022, showing a 12% increase in revenue from continuing operations compared to the previous year. Revenue reached $146 million, driven by growth in both Life Sciences Products and Services. Diluted EPS from continuing operations was ($0.02) per share, while non-GAAP diluted EPS was $0.12.

Azenta reported a strong start to fiscal year 2022, with revenue from continuing operations reaching $140 million, an 18% increase year-over-year, driven by robust demand for product and service offerings.

Brooks Automation reported strong financial results for Q4 2021, with revenue from continuing operations up 27% year over year. The company's Life Sciences business delivered another quarter of growth in excess of 20%.

Brooks Automation reported a revenue of $315 million for the third quarter of fiscal year 2021, representing a 43% increase year-over-year. Diluted EPS from continuing operations was $0.53 per share, compared to $0.19 per share in the third quarter of 2020.

Brooks Automation reported record revenue for the second quarter of fiscal year 2021, driven by growth in both Life Sciences and Semiconductor Solutions. The company also announced plans to separate into two independent, publicly traded companies.

Brooks Automation reported a strong Q1 2021 with revenue up 19% year-over-year, driven by growth in both Life Sciences and Semiconductor Solutions. The company's diluted EPS from continuing operations was $0.36 per share, compared to $0.18 per share in the same quarter last year.

Brooks Automation reported a strong fourth quarter with revenue up 24% year-over-year, driven by growth in both Semiconductor Solutions and Life Sciences businesses. Diluted EPS from continuing operations was $0.39 per share, compared to $0.07 per share in the fourth quarter of 2019. The company's operating margin also expanded, contributing to the earnings growth.

Brooks Automation reported revenue of $220 million, up 8% year-over-year, and diluted EPS of $0.19 per share, compared to $0.01 per share in the third quarter of 2019. The company's Life Sciences business witnessed robust demand, and Semiconductor saw increased demand for automation systems and robots.

Brooks Automation reported revenue of $220 million, representing an 11% year-over-year increase. The diluted EPS from continuing operations was $0.12, compared to a loss of ($0.04) in the same quarter last year. Both Semiconductor Solutions and Life Sciences segments experienced double-digit revenue growth.

Brooks Automation reported a strong first quarter of fiscal year 2020, with revenue reaching $210 million, a 17% increase year-over-year. Diluted EPS from continuing operations doubled to $0.18, and the company saw growth in both its Semiconductor Solutions and Life Sciences segments. The company is on track for a strong year, with significant contributions from Contamination Control Solutions and improved gross margins in Life Sciences Sample Management.